Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Cyprotex
Cyprotex
Activities:
Regulatory
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Analysis
Cyprotex expands its bioanalytical capabilities
To meet the requirements of existing and potential new customers
Research & Development
Cyprotex acquires CeeTox
Broadens toxicological assay and screening capabilities
Research & Development
Cyprotex to expand its UK facility into BioHub at Alderley Park
Will provide additional capacity for laboratories and office space
Research & Development
Cyprotex reports good performance across all parts of the business in first half
Gains new investors and raises £7m in cash to be used for further investment in the US and to assist with acquisitions
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Interview: Medicines and meteorites
ADME-Tox, good quality medicines and meteorites are three things that Tony Baxter, CEO of Cyprotex in Macclesfield, UK and Boston, US is keen on. He tells Jane Ellis why
Manufacturing
Cyprotex wins US government contract
Will provide high content imaging analysis for EPA ToxCast Project
Research & Development
Cyprotex launches eCiphrCardio cardiotoxicity service
To assess compounds in early drug development
Subscribe now